/PRNewswire/ The pulmonary arterial hypertension (PAH) drugs market size is forecasted to increase by USD 2,080.07 million from 2022 to 2027, at a CAGR of 6..
Ms. Yañez brings deep category experience and will lead Aerami’s focus on cardiopulmonary disease as AER-901 (inhaled imatinib) nears initiation of Phase 2.
Aerami Therapeutics Appoints Lisa Yañez as Chief Executive Officer - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ Faron Pharmaceuticals Ltd. ("Faron" or "Company") Faron Financial Statement Release January 1 to December 31, 2021 Financial statement release.
/PRNewswire/ Aerami Therapeutics Holdings, Inc. ("Aerami"), a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory.